Sana Biotechnology Highlights Publication In Nature Biotechnology Of Novel In Vivo Preclinical Data Showing Potential For Pluripotent Stem Cell-Derived Human Glial Progenitor Cell Transplantation As Treatment For Huntington's Disease And Other Glial-based Neurodegenerative Conditions

5/21/24 9:02:58 AM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $SANA alert in real time by email

Healthy transplanted human glial cells replaced diseased glial cells in the brains of human glial chimeric Huntingtin mice

Additional proof-of-concept for the advancement of SC379, Sana's pluripotent stem cell-derived glial progenitor cell product candidate

Get the next $SANA alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$SANA

Date	Price Target	Rating	Analyst
11/5/2024		Mkt Outperform → Mkt Perform	JMP Securities
6/26/2024	$16.00	Buy	Rodman & Renshaw
1/16/2024	$12.00	Neutral → Buy	H.C. Wainwright
9/25/2023	$9.00	Mkt Outperform	JMP Securities
9/5/2023	$8.00	Buy	Citigroup
8/14/2023		Market Perform	TD Cowen
5/2/2023		Neutral	H.C. Wainwright
8/6/2021	$39.00 → $34.00	Neutral	Goldman Sachs

More analyst ratings

$SANA
Press Releases

Fastest customizable press release news feed in the world

Flagship Pioneering Appoints Angela Hwang as CEO-Partner and Chief Executive Officer of Metaphore Biotechnologies
CAMBRIDGE, Mass., Nov. 20, 2024 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and Metaphore Biotechnologies, a Flagship-founded biotechnology company designing novel therapeutics by combining machine learning and molecular mimicry, today announced that Angela Hwang, MBA, will join Flagship Pioneering as CEO-Partner, and Metaphore as Chief Executive Officer, effective January 1, 2025. Most recently, Hwang served as Chief Commercial Officer and President of the Global Biopharmaceuticals Business at Pfizer. During her tenure at Pfizer, Hwang helped brin
11/20/24 8:00:00 AM ET
$FHTX
$MRNA
$OMGA
$SANA
Biotechnology: Pharmaceutical Preparations
Health Care
Biotechnology: Biological Products (No Diagnostic Substances)
Flagship Pioneering Announces Two New Agreements with Ampersand Biomedicines and Montai Therapeutics Under its Strategic Partnership with Pfizer
Ampersand's AND™ Platform will be used to identify programmed biologics for the treatment of obesity-related targets Montai's CONECTA™ AI platform will be used to identify small molecules directed to a potential Non-Small Cell Lung Cancer-related target Collaborations will leverage Pfizer's deep expertise in early discovery and development for cardiometabolic and cancer treatments, two priority therapeutic areas for the company CAMBRIDGE, Mass., Nov. 20, 2024 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, today announced Ampersand Biomedicines and Montai Therapeutics have entered into agreements to identify targeted molecules that could potentially be further dev
11/20/24 6:30:00 AM ET
$FHTX
$MRNA
$OMGA
$SANA
Biotechnology: Pharmaceutical Preparations
Health Care
Biotechnology: Biological Products (No Diagnostic Substances)
Flagship Pioneering Appoints Craig Williams as CEO-Partner and Chief Executive Officer of Apriori Bio
Williams was promoted from Operating Partner at Flagship Pioneering and President at Apriori Bio Apriori Bio has made significant progress in 2024, including securing a collaboration with CEPI, assembling a world class board of directors and building out an early pipeline of prospective vaccines CAMBRIDGE, Mass., Nov. 13, 2024 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and Apriori Bio, a biotechnology company aimed at providing humanity with variant-resilient protection against rapidly-evolving viruses, today announced that Craig Williams, MBA, has been promoted to CEO-Partner at Flagship Pioneering and Chief Executive Officer of Apriori.
11/13/24 8:00:00 AM ET
$FHTX
$MRNA
$OMGA
$SANA
Biotechnology: Pharmaceutical Preparations
Health Care
Biotechnology: Biological Products (No Diagnostic Substances)

$SANA
Leadership Updates

Live Leadership Updates

Flagship Pioneering Appoints Angela Hwang as CEO-Partner and Chief Executive Officer of Metaphore Biotechnologies
CAMBRIDGE, Mass., Nov. 20, 2024 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and Metaphore Biotechnologies, a Flagship-founded biotechnology company designing novel therapeutics by combining machine learning and molecular mimicry, today announced that Angela Hwang, MBA, will join Flagship Pioneering as CEO-Partner, and Metaphore as Chief Executive Officer, effective January 1, 2025. Most recently, Hwang served as Chief Commercial Officer and President of the Global Biopharmaceuticals Business at Pfizer. During her tenure at Pfizer, Hwang helped brin
11/20/24 8:00:00 AM ET
$FHTX
$MRNA
$OMGA
$SANA
Biotechnology: Pharmaceutical Preparations
Health Care
Biotechnology: Biological Products (No Diagnostic Substances)
Flagship Pioneering Appoints Craig Williams as CEO-Partner and Chief Executive Officer of Apriori Bio
Williams was promoted from Operating Partner at Flagship Pioneering and President at Apriori Bio Apriori Bio has made significant progress in 2024, including securing a collaboration with CEPI, assembling a world class board of directors and building out an early pipeline of prospective vaccines CAMBRIDGE, Mass., Nov. 13, 2024 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and Apriori Bio, a biotechnology company aimed at providing humanity with variant-resilient protection against rapidly-evolving viruses, today announced that Craig Williams, MBA, has been promoted to CEO-Partner at Flagship Pioneering and Chief Executive Officer of Apriori.
11/13/24 8:00:00 AM ET
$FHTX
$MRNA
$OMGA
$SANA
Biotechnology: Pharmaceutical Preparations
Health Care
Biotechnology: Biological Products (No Diagnostic Substances)
Brian M. Alexander Joins Valo Health as Chief Executive Officer and Flagship Pioneering as CEO-Partner
Valo Elevates Brett Blackman to Chief Operating Officer and Appoints Travis Wilson to its Board of Directors CAMBRIDGE, Mass., Nov. 13, 2024 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and Valo Health today announced that industry leader Brian M. Alexander, M.D., M.P.H. has been appointed Chief Executive Officer of Valo Health and CEO-Partner of Flagship Pioneering. Dr. Alexander brings two decades of biotechnology, biopharma, and medical leadership, most recently as SVP, Research & Development and Head of Boston Roche Innovation Center (BRIC), for Roche/Genentech and previously as CEO of Foundation Medicine. Valo also announced the appointments of Brett Blackman
11/13/24 8:00:00 AM ET
$FHTX
$MRNA
$OMGA
$SANA
Biotechnology: Pharmaceutical Preparations
Health Care
Biotechnology: Biological Products (No Diagnostic Substances)

Sana Biotechnology Highlights Publication In Nature Biotechnology Of Novel In Vivo Preclinical Data Showing Potential For Pluripotent Stem Cell-Derived Human Glial Progenitor Cell Transplantation As Treatment For Huntington's Disease And Other Glial-based Neurodegenerative Conditions

Chat with this insight

Recent Analyst Ratings for $SANA

$SANA Press Releases

Fastest customizable press release news feed in the world

Flagship Pioneering Appoints Angela Hwang as CEO-Partner and Chief Executive Officer of Metaphore Biotechnologies

Flagship Pioneering Announces Two New Agreements with Ampersand Biomedicines and Montai Therapeutics Under its Strategic Partnership with Pfizer

Flagship Pioneering Appoints Craig Williams as CEO-Partner and Chief Executive Officer of Apriori Bio

$SANA Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Nelsen Robert bought $9,999,996 worth of shares (1,818,181 units at $5.50) (SEC Form 4)

Crandell Keith bought $9,999,996 worth of shares (1,818,181 units at $5.50) (SEC Form 4)

Arch Venture Fund X, L.P. bought $9,999,996 worth of shares (1,818,181 units at $5.50) (SEC Form 4)

$SANA Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Sana Biotechnology downgraded by JMP Securities

Rodman & Renshaw initiated coverage on Sana Biotechnology with a new price target

Sana Biotechnology upgraded by H.C. Wainwright with a new price target

$SANA Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Sana Biotechnology Inc.

Amendment: SEC Form SC 13G/A filed by Sana Biotechnology Inc.

Amendment: SEC Form SC 13G/A filed by Sana Biotechnology Inc.

$SANA SEC Filings

SEC Form 10-Q filed by Sana Biotechnology Inc.

Sana Biotechnology Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

Sana Biotechnology Inc. filed SEC Form 8-K: Leadership Update

$SANA Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Amendment: New insider Fmr Llc claimed ownership of 61 shares (SEC Form 3)

New insider Wyrick Susan D. claimed ownership of 147,512 shares (SEC Form 3)

Director Bishop Hans Edgar was granted 5,938 shares, increasing direct ownership by 0.10% to 5,790,489 units (SEC Form 4)

$SANA Leadership Updates

Live Leadership Updates

Flagship Pioneering Appoints Angela Hwang as CEO-Partner and Chief Executive Officer of Metaphore Biotechnologies

Flagship Pioneering Appoints Craig Williams as CEO-Partner and Chief Executive Officer of Apriori Bio

Brian M. Alexander Joins Valo Health as Chief Executive Officer and Flagship Pioneering as CEO-Partner

$SANA Market Insights

Live Market Insights

Why Charles Schwab Shares Are Trading Lower By Over 7%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

Sana Biotechnology Highlights Publication In Nature Biotechnology Of Novel In Vivo Preclinical Data Showing Potential For Pluripotent Stem Cell-Derived Human Glial Progenitor Cell Transplantation As Treatment For Huntington's Disease And Other Glial-based Neurodegenerative Conditions

HC Wainwright & Co. Reiterates Buy on Sana Biotechnology, Maintains $12 Price Target

Recent Analyst Ratings for
$SANA

$SANA
Press Releases

$SANA
Insider Purchases

$SANA
Analyst Ratings

$SANA
Large Ownership Changes

$SANA
SEC Filings

$SANA
Insider Trading

$SANA
Leadership Updates

$SANA
Market Insights